The US FDA approved MedRegen’s IND application for a combined phase I/II trial with MRG-001 for targeting COVID-19 patients.
The US FDA approved MedRegen’s IND application for a combined phase I/II trial with MRG-001 for targeting COVID-19 patients.
Optimized by Seraphinite Accelerator